secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001104659-25-029666
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma
--------------------------------------------------------------------------------

- Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
- Cash and equivalents $19.2M at Dec 31, 2024; funds operations into Q1 2026 without additional grants.
- Phase 1 APOLLO study: MT-601 (neldaleucel) achieved 78% objective response rate (7/9) with 44.4% complete responses; well-tolerated.
- Secured $13M+ in non-dilutive funding from CPRIT ($9.5M) and NIH SBIR ($2M) for pancreatic and lymphoma programs.
- December 2024 private placement raised $16.1M from new and existing investors including Blue Owl, NEA, Aisling Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/0001104659-25-029666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/tm2510813d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer